DELETE - Pharmaceutical Executive

ADVERTISEMENT

DELETE

Meetings: Overall Improvement

April 1, 2005

You would think that identifying where a pharma company spends its money on meetings would be simple, but at most organizations, there are no processes or systems in place to track meeting activity.

Thought Leader: Better Business: Balancing Benefit, Risk, and Cost

April 1, 2005

Lower-priced drugs used by more patients may meet public health needs, as well as business needs, better than the often rapacious pricing we now see. This will become clearer with likely cutbacks in drug spending of Medicaid this year, and in the planned Medicare benefit next year.

Leadership: Listen Up Leaders: Get Out of the Way!

April 1, 2005

Creativity that spawns innovation transcends the daily workplace grind and shows up in unexpected areas.

Newer Not Always Better

April 1, 2005

Developing first-in-class therapies is riskier and more labor intensive than filling pipelines with successor drugs. Can innovation remain the cornerstone of an industry reliant on "me toos"?

Marketing to Professionals: The Good and the Bad

April 1, 2005

Companies should balance the public's need to know with the industry's right to keep strategic intelligence private.

Direct to Consumer: Is Branding Enough?

April 1, 2005

You couldn't have missed Viagra's (sildenafil) "Devi" campaign. It's the one where the "V" in the Viagra logo turns into a pair of devil"s horns atop a middle-aged man's head. Well, FDA didn"t miss it either. Back in November 2004, the agency sent Pfizer a warning letter stating that its reminder ads for Viagra lacked risk information.

Pharma's New Face

March 1, 2005

We accept risk in every phase of our lives except drugs. There is a lot of risk to open-heart surgery. But I don’t hear anyone saying we need to stop doing it.

Back Page: States Won't Wait for Feds

March 1, 2005

In 2002 it was the PhRMA Code, in 2003 it was the OIG's Guidance for Industry, and in 2004 it was Justice Department enforcement. Now, in 2005, it appears that regulation of the US pharma industry has a new focal point—state legislatures.

Marketing to Professionals: Marketing to Go

March 1, 2005

Outsourcing is common among start-ups, with limited income to invest in marketing. It makes sense for larger companies with products that lack blockbuster potential.

ADVERTISEMENT

Click here